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ABSTRACT
Introduction: In the developed world,
Clostridium difficile infection (CDI) is the most
important cause of nosocomial infectious
diarrhea. In addition to providing
epidemiological data and helping to indicate
that a local outbreak may be occurring,
laboratory tests are used to augment clinical
decisions on individual patients. Very rarely do
diagnostic tests provide results at the point of
decision making; in the intervening period
between requesting investigations on a patient
with suspected CDI and return of the laboratory
result, decisions must be made regarding
patient isolation and treatment.
Methods: A 22-month, real-world feasibility
study was conducted in patients with clinically
significant diarrhea, in a London Hospital
between March 2011 and January 2013, in
three older persons’ wards and two intensive
care units (ICUs) to determine acceptability,
ease of use, change in turnaround time and
clinical utility of a rapid, polymerase chain
reaction (PCR)-based point-of-care test (POCT)
(Cepheid GeneXpert, Sunnyvale, California,
USA) for diagnosis of Clostridium difficile. Nurses
in the older persons’ ward and laboratory
technicians in the ICU were trained to
perform the test. Residual samples were sent to
the centralized laboratory for parallel testing
using a two-step algorithm.
Results: A total of 335 samples were tested using
the POCT with a median turnaround time of
1.85 h compared with 18 h for the centralized
laboratory test. Overall agreement with
centralized laboratory testing was 98.1%.
Discrepant samples were more frequent on
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elderly wards than ICU. Overall 20/335 (6%)
processing errors were encountered and were
highest in the first few months of the study.
Significantly more processing errors occurred on
the older persons’ wards 13/102 (12.7%) than on
ICU 7/271 (2.6%). Older persons’ patients who
had POCT were significantly less likely to have a
test requested for bacterial stool culture (3.1% vs.
10.9% p = 0.044). This difference was not
observed in the ICU patients. No other
differences in ancillary test requesting,
mortality or length of stay were observed.
Conclusions: The majority of users reported
that the POCT was easy to perform and was an
acceptable part of their job. POCT using this
system is feasible and acceptable to nursing staff
and technicians working within these two
hospital-based settings.
Keywords: Clostridium difficile; Infection;
Nosocomial infectious diarrhea; Point-of-care
testing; Rapid diagnostics
INTRODUCTION
Diarrhea is a common symptom in hospitalized
patients; however, the majority of patients have
a non-infectious etiology [1]. In the developed
world, Clostridium difficile infection (CDI) is the
most important cause of nosocomial infectious
diarrhea [2]. In addition to providing
epidemiological data and helping to indicate
that a local outbreak may be occurring,
laboratory tests are used to augment clinical
decisions on individual patients. Very rarely do
diagnostic tests provide results at the point of
decision making; in the intervening period
between requesting investigations on a patient
with suspected CDI and return of the laboratory
result, decisions must be made regarding
patient isolation and treatment.
The average time taken to test for CDI in
one study was 1.8 days [3], although other
centers performing testing three times per day
report turnaround times of 8 h [4]. The
authors have previously reported a median
turnaround time of 17.3 h in their
institution’s laboratory [1]. As a consequence
of diagnostic delays, patients are often
presumptively isolated and treated for CDI
empirically. For those patients who ultimately
test positive, this may be beneficial in terms of
preventing cross transmission [5] and
improving clinical outcomes; however,
isolating a patient with diarrhea due to a
non-infectious cause may be wasteful of scarce
resources. Similarly, empirical anti-C. difficile
treatment may be detrimental to patients.
Other studies have found that as much as
40–62% of empirical therapy for C. difficile is
inappropriate [3, 6]. Thus, there is a clinical
need for a rapid diagnostic test that can help
clinicians make informed decisions quicker,
minimizing waste and potentially improving
clinical outcomes.
The majority of microbiology tests are
performed in centralized laboratories;
however, delays are encountered due to two
main bottlenecks: transportation to the
laboratory and batching of specimens to be
tested. There has been a recent trend towards
centralization and consolidation of pathology
services, which can adversely affect
turnaround times [7, 8]. These problems may
be partially resolved by the use of point-of-
care tests (POCT), which have been introduced
for a number of infectious diseases [7–14]. The
rapid turnaround times of POCTs are
potentially beneficial for making decisions in
a variety of situations: isolation of infectious
patients (and de-isolation of non-infectious
ones); avoidance of unnecessary
hospitalization; avoidance of unnecessary
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treatment (including reduced length of
therapy); and improved selection of
antimicrobial therapy (e.g., using a more
appropriate, narrower spectrum agent) [7].
There are few reports in the literature of
efforts to reduce laboratory turnaround times
for C. difficile testing. Verdoorn and colleagues
assessed the effect of telephoning out positive
C. difficile results on the time to ordering
antimicrobial therapy, which was reduced
from a mean of 11.9–3.6 h [15]. Barbut and
colleagues noted that changing their laboratory
testing from a cytotoxicity assay to either PCR
alone or in combination with glutamate
dehydrogenase (GDH) led to a significant
reduction in turnaround time from a mean of
3.5–0.55 days. This was associated with a
reduction in unnecessary empirical therapy,
length of stay and a non-significant reduction
in mortality [16].
The present literature on real-world
assessment of POCT for infectious diseases is
limited [9] and no studies have evaluated C.
difficile testing in a near-patient environment.
This is mostly due to the lack of commercially
available assays that can be used for this
purpose. However, several manufacturers are
developing highly sensitive molecular-based
tests that could be implemented at POCT.
These tests have been proposed or evaluated in
a number of infectious diseases e.g., MRSA [10],
influenza [17], sexually transmitted infections
[11], group B Streptococcus [12], tuberculosis [13]
and HIV [14].
The authors performed a feasibility study to
evaluate acceptability, ease of use, change in
turnaround time and clinical utility of a rapid,
polymerase chain reaction (PCR) POCT
(Cepheid GeneXpert, Sunnyvale, California,
USA) in three older persons’ wards and two
intensive care units (ICUs).
METHODS
Setting
The study was conducted in a central London
academic hospital, with 1,100 beds, including
180 individual isolation rooms. Patients
admitted with or who develop diarrhea and/or
vomiting are placed in these rooms (with
private bathroom), and kept there until at
least 48 h following return to normal bowel
habit. If this is not possible, the patient is placed
in a cohorted, or an otherwise unoccupied, bay.
Clinicians are advised to investigate all cases of
diarrhea (two or more liquid stools in 24 h). The
rate of CDI in our institution between April
2011 and March 2012 was 32.2 cases per
100,000 occupied bed days (OBD). This
compares to a national rate of 61.9 cases per
100,000 OBD for the same period.
The UK does not define technical criteria for
assessing the suitability of POCT; however,
there are local guidelines which are overseen
by a Point of Care Committee in our hospital
[18].
The study was conducted between March
2011 and January 2013 (22 months) in two
settings; three adjacent older persons’ wards
comprising a total of 85 beds, and two adjacent
ICUs comprising a total of 30 beds. Comparator
wards, consisting of one older persons’ ward
and one ICU, had access only to laboratory-
based testing and were used to compare study
wards to investigate potential clinical utility.
Members of staff were asked to test any
patient with clinically significant diarrhea for
CDI using the POCT (GeneXpert); the residual
sample was then tested in the centralized
laboratory. The GeneXpert system (Cepheid,
Sunnyvale, California, USA) is an automated,
disposable cartridge based, real-time PCR assay
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which detects the genes for toxin B (tcdB),
binary toxin (cdt) and a point mutation
associated with PCR ribotype 027. A positive
for the toxin B target indicates that toxigenic C.
difficile has been detected; the two other targets
provide information about the presence of
presumptive ribotype 027. Two GeneXpert
systems were placed in the utility rooms of the
three adjacent older persons’ wards. The ICU
has its own co-located satellite laboratory,
capable of performing a range of near-patient
tests, into which a GeneXpert system was
placed.
The residual stool sample was sent to the
centralized laboratory for testing in parallel
using a two-step algorithm [19] which
comprised GDH (GDH Chek-60, TechLab,
Blacksburg, Virginia, USA), with PCR
(GeneXpert) as a confirmatory step for
positives. Results from both testing methods
together with turnaround times (from point of
sample requesting to availability of result) were
compared using the same sample.
Compliance with Ethics Guidelines
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(London City and East Research Ethics
Committee) and with the Helsinki Declaration
of 1975, as revised in 2000 and 2008. Informed
consent was obtained from all patients for being
included in the study.
Staff Training
Nurses, healthcare assistants (older persons’
wards) and laboratory technicians (ICUs) were
trained to use the POCT system by a research
nurse. This generally took around 1 h and was
done in small groups. Training consisted of a
demonstration followed by direct observation
of each staff member to ensure competence.
Competent staff members were provided with a
password to operate the GeneXpert system.
Additional training was provided to those
requiring it. The research nurse was available
between the hours of 9 am and 5 pm, Monday
to Friday, to assist with any problems and train
new staff members.
Connectivity and Results
The GeneXpert systems were networked using
Synapse software (Systelab Technologies S.A.,
Barcelona, Spain). This allowed real-time
monitoring of test results and errors on all
GeneXpert systems. The analyzers were not
interfaced directly with either the Laboratory
Information Management System or the
Electronic Patient Record. The GeneXpert
analyzers were connected to printers, which
automatically printed out individual patient
results upon test completion. Staff members
on older persons’ wards were instructed to
insert this into the patient’s clinical notes;
staff in ICU manually transferred the result to
the Electronic Patient Record. Additionally,
whenever any sample tested positive, an
immediate automated email alert was sent to
the study team and service infection control
nurses from 9 am to 5 pm, Monday to Friday.
Outside of these hours, infection control advice
was provided by an infectious diseases/
microbiology physician. This allowed
immediate notification of a case and
subsequent infection control interventions to
be implemented before the centralized
laboratory testing result became available.
Clinical staff were instructed to act upon the
results as they would have had the sample been
processed in the centralized laboratory.
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Clinical Utility
Patients who underwent testing with the POCT
were age and sex matched with patients tested
for CDI on non-study wards (older persons’
ward or ICU) where POCT testing was not
available. These groups were compared to
determine any differences in length of stay,
30-day all-cause mortality and requesting of
certain ancillary investigations e.g., stool
culture, norovirus testing, radiological
investigations etc.
Acceptability and Ease of Use
A questionnaire was designed to gauge users’
experience and opinions on the POCT. A five-
point scale was used to assess level of agreement
with five statements covering ease of use,
acceptability, turnaround time, and effect on
bed management.
RESULTS
The study period lasted for 22 months (March
2011 to January 2013). During this time, a total
of 330 patients were tested by the POCT; 97
(29%) POCTs were performed on the older
persons’ wards and 233 (71%) on ICU. A total
of 335 POCTs were performed; 100 tests on the
97 elderly patients and 235 tests were performed
on the 233 ICU patients.
A total of 76 older persons’ staff were trained,
comprising of 17 healthcare assistants with no
formal qualifications, 46 junior or student
nurses and 13 senior nurses. Each older
persons’ staff member processed an average of
1.3 tests. A total of 15 ICU laboratory
technicians were trained, each processing an
average of 18 tests.
The majority of POCTs performed on older
persons’ wards were undertaken between the
hours of midday and 9 pm (82%). This figure
was lower for those performed in ICU (61%).
Figure 1 shows times of sample testing on the
older persons’ wards and ICUs.
Turnaround Time
The median total turnaround time for
laboratory-based testing (from the point of test
ordering to the point of result availability) was
18 h, with a median laboratory analytical
turnaround time of 9.1 h. The majority of the
time difference was accounted for by sample
transportation. The median total turnaround
time for all samples tested by POCT was 1.85 h.
The median turnaround time for POC tests
processed on ICU (2.35 h) was slightly longer
than that for tests processed on older persons’
wards (0.83 h).
Agreement with Laboratory Testing
Of the 335 samples that were tested using the
POCT, 20 (6%) were either not received by the
laboratory or there was insufficient material to
perform further testing. Of the remaining 315
samples, 274 (87%) were negative by both
POCT and laboratory-based GDH, and 15
(4.8%) were negative by POCT, positive by
laboratory-based GDH but negative by
laboratory-based PCR; these samples were
considered to be non-discrepant. The
remaining 26 (8.2%) samples were positive by
POCT; of these 20 were also laboratory-based
GDH and PCR positive (considered non-
discrepant) and 6 were laboratory-based GDH
negative (considered discrepant). Overall
agreement was 98.1%. In total, there were 6
(1.9%) discrepant samples with a mean cycle
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threshold (Ct) value of 32.9. The maximum
valid Ct for the toxin B target is 37. Discrepant
samples were more likely to occur on elderly
wards (n = 3, 3.9% of those tested) than ICU
(n = 3, 1.3% of those tested), although this was
not significant.
Processing Errors
Overall 20/335 (6%) processing errors were
encountered where a result was not obtained.
These resulted from a variety of user and
platform errors and were greatest in the first
few months of the study (ten (20.4%) errors in
49 tests performed in quarter one compared
with two (3.3%) errors in 61 tests performed in
quarter five). During the second half of the
study, an updated GeneXpert cartridge was
introduced by the manufacturer, which had
pre-filled reagents; this further simplified assay
setup and reduced hands on time, although this
did not have any effect on the number of
processing errors. Overall, significantly more
processing errors occurred on the older persons’
wards 13/102 (12.7%) than on ICU 7/271 (2.6%)
p =\0.001.
Clinical Utility
The mean age of all patients tested with the
POCT was 66 years; with a lower mean age in
the ICU patients (59 years) compared with older
persons’ patients (85 years). A greater
proportion of patients tested positive in the
older persons’ wards (14.4% and 17.4% of those
tested by the POCT and the laboratory-based
test, respectively) compared with ICU patients
(6.9% and 6.6% of those tested by the POCT
and the laboratory-based test, respectively).
Overall, most patients were tested well into
their hospital admission (mean of 16 days
following admission). This corresponds with a
high proportion of patients being classified as
having hospital-associated diarrhea (onset of
symptoms on day 3 or more following
admission). However, of the older persons’
Fig. 1 Time of sample processing for POCT for older persons’ wards (black) and ICU (gray). ICU Intensive care unit,
POCT point-of-care test
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patients, significantly more had hospital onset
diarrhea in those tested with the laboratory-
based test only (97% compared with 84% for
those were tested with the POCT).
Differences in patient demographics,
ancillary clinical investigations and outcomes
between patients tested by POCT and those in
comparator wards tested in the laboratory are
shown in Table 1. There were no significant
differences in terms of length of stay and all-
cause mortality rates. Overall 30-day all-cause
mortality rate was 5.1 per 1,000 inpatient days
(25.3%), which is slightly less than that
reported elsewhere [20]. Older persons’
patients who had POCT were significantly less
likely to have a test requested for bacterial stool
culture (3.1% vs. 10.9% p = 0.044). This
difference was not observed in the ICU
patients. No other differences in ancillary test
requesting were observed.
Acceptability and Qualitative Feedback
from Operators
A user questionnaire was completed by 85 staff
members in two phases (40 in phase one and 45
in phase two, following the introduction of the
new GeneXpert cartridges). Staff were
permitted to participate in both phases. Sixty-
six respondents (78%) were older persons’ staff
and 19 (22%) were ICU staff. All ICU staff in
both rounds agreed that the test was easy to
perform, compared with 76% of older persons’
staff. The proportion of older persons’ staff who
agreed with this comment was no different in
either phase of the questionnaire. All ICU
respondents and 88% of older persons’
respondents agreed that POCT results were
available faster than laboratory testing.
Seventy-six percent of ICU respondents liked
being able to perform the test themselves and
94% felt it was an acceptable part of their role.
This compares with 86% and 80%, respectively,
in older persons’ respondents. 95% of ICU
respondents and 86% of older persons’
respondents thought that the test had helped
them to manage beds more effectively (Fig. 2).
DISCUSSION
Diarrhea and CDI are major infection control
challenges for hospitals and clinicians must
decide on the most efficient use of scarce
resources. Laboratory-based testing for C.
difficile is sometimes slow but POCT could
provide a faster result.
The data show that use of this POCT system
is feasible in both the older persons’ wards and
the ICUs studied. However, more problems were
encountered in the older persons’ wards (more
discrepant results and more processing errors).
Although most older persons’ staff reported that
the test was easy to perform, this staff group are
unfamiliar with carrying out this type of
procedure. The ICU technicians were much
more familiar with basic laboratory processes
and this may account for the lower number of
discrepant results and processing errors. The
number of errors did not appear to decrease
after the introduction of the updated
GeneXpert cartridge.
The six discrepant samples raise the
possibility of contamination during assay
preparation; all had relatively high Ct values.
During training, users were educated about the
importance of keeping the equipment and work
areas clean and the disposable, single use nature
of the cartridges and minimal sample handling
to reduce the risk of contamination.
The processing errors could be related to the
low volumes of tests being performed by any
one individual staff member (particularly for
the older persons’ staff who processed an
average of just one test each for the duration
Infect Dis Ther (2014) 3:295–306 301
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of the study). A higher throughput of tests may
have helped staff members to confidently recall
how to perform the procedure. A more
successful model of testing may be to make
use of staff that are more familiar with
laboratory procedures in a dedicated satellite
POC laboratory [7]. Cohen-Bacrie and
colleagues describe this model in their
Marseilles hospitals and were able to achieve
turnaround times between 0.5 and 3.5 h for a
range of 23 POCTs of varying complexity [7].
Gray and colleagues found that assigning
responsibility for Group B Streptococcus testing
in laboring women to a relatively small group of
staff ensured that each tester undertook enough
testing to maintain competency [12]. With any
POCT, there is a need for staff performing the
test to be trained and competent in appropriate
documentation, sample collection, performing
the test and result interpretation. Failure to do
this can have adverse outcomes in terms of
assay performance [9].
Most tests were performed during the
afternoon or early evening on the older
persons’ wards, whereas tests were performed
throughout the day and night on the ICU. The
numbers of nursing staff on the older persons’
wards was lower through the night shift, but
remained stable on the ICU. Patients may also
be less willing to report diarrhea during the
night and many patients on ICU were fitted
with bowel managers making access to stool
samples easier. In a study of POC testing for
Group B Streptococcus in a UK delivery suite,
Gray and colleagues found that testing
increasingly became confined to normal
working hours, when laboratory staff were
available to assist [12].
The turnaround time of the POCT was
significantly faster compared with laboratory-
Fig. 2 Acceptability and ease of use. A total of 66 older
persons’ staff and 19 ICU laboratory technicians completed
a user questionnaire, asking the level of agreement or
disagreement with ﬁve statements based on a scale of 1
(completely agree) to 5 (completely disagree). The questions
were as follows: (1) the POCT is easy to perform, (2)
results from the POCT are available faster than the
laboratory-based test, (3) I like being able to perform the
POCT myself, (4) performing the POCT is an acceptable
part of my role, (5) the POCT results have allowed better
management of beds. ICU Intensive care unit, POCT
point-of-care test
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based testing (1.85 vs. 18 h, respectively).
Sample transportation caused a significant
delay in our institution, batching of samples
testing in the centralized laboratory also added
on additional time, even when samples were
tested twice per day. Although the turnaround
time was significantly reduced, there were no
discernable effects of the POCT on clinical
utility other than a reduction in ancillary
bacterial culture testing. This is likely to be a
minimal cost saving and does not offset the
significant costs of running the POCT. The
numbers in this study were modest and the
study may be insufficiently powered to detect
any changes in clinical outcomes between those
tested with POCT compared with those tested
by laboratory-based testing. Future studies
should look at other outcomes such as severity
of disease, time to anti-C. difficile therapy (or de-
escalation of empiric therapy) and use of
isolation facilities. It would be prudent to bear
in mind, however, that a negative result for C.
difficile does not necessarily mean that the
patient can be removed from single room
isolation, since the symptoms could be due to
another infectious cause such as norovirus.
Ideally the patient would be tested for a range
of infectious agents to be confident that they do
not pose a risk of cross transmission before de-
isolating [1].
UK and European guidance recommends
testing for CDI using a two-step algorithm
with either GDH or a molecular test as a first
stage and confirming any positives with a toxin
enzyme immunoassays (EIA) [21, 22]. This
study was conceived and carried out before
this guidance was published and there is still
debate about the clinical interpretation of PCR
positive tests in diarrheal patients [23].
Given the current testing guidelines
endorsed by Public Health, England and
European Society of Clinical Microbiology and
Infectious Diseases (ESCMID), perhaps there
could be additional value of this assay in
screening newly admitted patients for
colonization. Asymptomatic carriage is
widespread amongst hospital inpatients [24]
and potential transmission from this group
has already been demonstrated [25]. Peri-rectal
swabs could provide a more convenient and
acceptable sample type for screening patients
[26]. The practice of screening for carriage is not
widely practiced, however, modeling has shown
that this approach may be cost effective [27].
Financial costs were not evaluated in this
study. However, when deciding to implement a
POCT, it is important to consider the often
hidden costs of support from a local accredited
laboratory, and costs of training and
maintenance; these should be measured in any
future evaluation.
CONCLUSION
This study demonstrates that POCT using the
GeneXpert system is feasible and acceptable to
nursing staff and technicians working within
the two extremes of these hospital-based
settings. The assay has already been used in a
variety of settings including in resource poor
countries [28, 29]. These types of tests are
becoming increasingly more common and it is
important that they are assessed in the
environment for which they are intended with
high-quality clinical utility studies, which also
evaluate cost effectiveness.
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